British Society of Gastroenterology guidelines on the management of irritable bowel syndrome

Published on Apr 26, 2021in Gut19.819
· DOI :10.1136/GUTJNL-2021-324598
Dipesh H. Vasant10
Estimated H-index: 10
(University of Manchester),
Peter Paine15
Estimated H-index: 15
(University of Salford)
+ 11 AuthorsAlexander C. Ford86
Estimated H-index: 86
(St James's University Hospital)
Sources
Abstract
Irritable bowel syndrome (IBS) remains one of the most common gastrointestinal disorders seen by clinicians in both primary and secondary care. Since publication of the last British Society of Gastroenterology (BSG) guideline in 2007, substantial advances have been made in understanding its complex pathophysiology, resulting in its re-classification as a disorder of gut-brain interaction, rather than a functional gastrointestinal disorder. Moreover, there has been a considerable amount of new evidence published concerning the diagnosis, investigation and management of IBS. The primary aim of this guideline, commissioned by the BSG, is to review and summarise the current evidence to inform and guide clinical practice, by providing a practical framework for evidence-based management of patients. One of the strengths of this guideline is that the recommendations for treatment are based on evidence derived from a comprehensive search of the medical literature, which was used to inform an update of a series of trial-based and network meta-analyses assessing the efficacy of dietary, pharmacological and psychological therapies in treating IBS. Specific recommendations have been made according to the Grading of Recommendations Assessment, Development and Evaluation system, summarising both the strength of the recommendations and the overall quality of evidence. Finally, this guideline identifies novel treatments that are in development, as well as highlighting areas of unmet need for future research.
📖 Papers frequently viewed together
200830.22BMJ
4 Citations
6 Citations
7 Citations
References296
Newest
#1Christopher J BlackH-Index: 13
#2Orla Craig (Leeds Teaching Hospitals NHS Trust)H-Index: 1
Last. Alexander C. FordH-Index: 86
view all 4 authors...
Objectives Despite being proposed 4 years ago, there has been no independent validation study of the Rome IV criteria for IBS. We assessed their performance for the diagnosis of IBS in secondary care and compared them with the previous iteration, the Rome III criteria. Design We collected complete symptom data from consecutive adult patients with suspected IBS referred to a single UK clinic. All subjects underwent relatively standardised workup, with assessors blinded to symptom status. The refe...
2 CitationsSource
#1Shin Fukudo (Tohoku University)H-Index: 54
#2Masatoshi NakamuraH-Index: 1
Last. Hiroto Miwa (Hyogo College of Medicine)H-Index: 54
view all 5 authors...
Abstract Background and aims Treatment options for irritable bowel syndrome with constipation (IBS-C) are limited—new prokinetic drugs are needed. We evaluated the efficacy and safety of minesapride (DSP-6952), a partial agonist with high affinity for 5-HT4 receptors, in patients with IBS-C in Japan. Methods We performed a double-blind phase 2 study of 171 patients with Rome III-defined IBS-C at 33 centers in Japan, from December 2012 through August 2013. Patients were randomly assigned to group...
5 CitationsSource
#1Robin C. Spiller (University of Nottingham)H-Index: 90
Irritable bowel syndrome (IBS), with its key features of abdominal pain and disturbed bowel habit, is thought by both patients and clinicians to be strongly influenced by diet. However, the complexities of diet have made identifying specific food intolerances difficult. Eating disorders can masquerade as IBS and may need specialist treatment. While typical food allergy is readily distinguished from IBS, the mechanisms of gut-specific adverse reactions to food are only just being defined. These m...
2 CitationsSource
#1Maura Corsetti (University of Nottingham)H-Index: 26
#2Steve Brown (University of Sheffield)H-Index: 19
Last. S. Mark Scott (QMUL: Queen Mary University of London)H-Index: 22
view all 20 authors...
Background Chronic constipation is a prevalent disorder that affects quality of life of patients and consumes resources in healthcare systems worldwide. In clinical practice, it is still considered a challenge as clinicians frequently are unsure as to which treatments to use and when. Over a decade ago, a Neurogastroenterology and Motility journal supplement devoted to the investigation and management of constipation was published (Neurogastroenterol Motil 2009;21(Suppl 2):1). In October 2018, t...
1 CitationsSource
#1Bridgette Wilson ('KCL': King's College London)H-Index: 3
#2Selina R Cox ('KCL': King's College London)H-Index: 5
Last. Kevin Whelan ('KCL': King's College London)H-Index: 63
view all 3 authors...
Dietary restriction of fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP) is clinically effective and a commonly utilised approach in the management of functional symptoms in irritable bowel syndrome. Despite this, the low FODMAP diet has a number of challenges: it can alter the gut microbiota; impact nutrient intake and diet quality; is complex to understand; requires the patient to be adequately supported to follow the diet accurately and safely; and lastly, not ...
1 CitationsSource
#1Brigida Barberio (UNIPD: University of Padua)H-Index: 7
#2Lesley A. Houghton (University of Leeds)H-Index: 53
Last. Alexander C. Ford (University of Leeds)H-Index: 86
view all 6 authors...
Introduction Irritable bowel syndrome (IBS) is a chronic functional bowel disorder, which follows a relapsing and remitting course. Little is known about how evolving definitions of IBS or treatment for the condition affect symptom stability. We conducted a 12-month longitudinal follow-up study of individuals who self-identified as having IBS to examine these issues. Methods We collected demographic, gastrointestinal symptom, mood, and psychological health data at baseline, and gastrointestinal ...
4 CitationsSource
#1William D. CheyH-Index: 78
#2Gregory S. Sayuk (WashU: Washington University in St. Louis)H-Index: 23
Last. Niels Borgstein (Ironwood Pharmaceuticals)H-Index: 3
view all 10 authors...
Introduction Immediate-release (IR) formulation of linaclotide 290 μg improves abdominal pain and constipation (APC) in patients with irritable bowel syndrome (IBS) with constipation. Delayed-release (DR) formulations were developed on the premise that targeting the ileum (delayed-release formulation 1 [DR1]) or ileocecal junction and cecum (MD-7246, formerly DR2) would modulate linaclotide's secretory effects while preserving pain relief effects. Methods This phase 2b study randomized patients ...
1 CitationsSource
#1Jordyn Feingold (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 3
#2Douglas A. DrossmanH-Index: 103
Stigma, defined as social devaluation based on negative stereotypes toward a particular population, is prevalent within health care and is a common phenomenon in disorders of gut-brain interaction (DGBI). Characteristically, DGBI including functional dyspepsia (FD) lack a structural etiology to explain symptoms, have high psychiatric co-morbidity, and respond to neuromodulators traditionally used to treat psychopathology. As a result, these disorders are frequently and wrongly presumed to be psy...
2 CitationsSource
#1Javier Aguilera-Lizarraga (Katholieke Universiteit Leuven)H-Index: 10
#2Morgane Florens (Katholieke Universiteit Leuven)H-Index: 6
Last. Guy E. Boeckxstaens (Katholieke Universiteit Leuven)H-Index: 79
view all 44 authors...
Up to 20% of people worldwide develop gastrointestinal symptoms following a meal1, leading to decreased quality of life, substantial morbidity and high medical costs. Although the interest of both the scientific and lay communities in this issue has increased markedly in recent years, with the worldwide introduction of gluten-free and other diets, the underlying mechanisms of food-induced abdominal complaints remain largely unknown. Here we show that a bacterial infection and bacterial toxins ca...
10 CitationsSource
#1Ami D. Sperber (BGU: Ben-Gurion University of the Negev)H-Index: 31
#2Shrikant I. Bangdiwala (McMaster University)H-Index: 75
Last. Olafur S. Palsson (UNC: University of North Carolina at Chapel Hill)H-Index: 50
view all 48 authors...
Abstract Background & Aims Although functional gastrointestinal disorders (FGIDs), now called disorders of gut–brain interaction, have major economic effects on healthcare systems and adversely affect quality of life, little is known about their global prevalence and distribution. We investigated the prevalence of and factors associated with 22 FGIDs, in 33 countries on 6 continents. Methods Data were collected via the internet in 24 countries, personal interviews in 7 countries, and both in 2 c...
74 CitationsSource
Cited By0
Newest
1 CitationsSource